On the origin of EEG-slowing and encephalopathy during induction treatment of acute lymphoblastic leukemia

Medical and Pediatric Oncology

Volumn 39, Issue 6, 2002, Pages 566-572

  Korinthenberg, Rudolf ^a,c   Scheuring, Bernadette ^a   Boos, Joachim ^b   Niemeyer, Charlotte ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Acute lymphoblastic leukemia; Childhood cancer; Cytostatic drugs; Electro encephalography; Neurotoxicity

Indexed keywords

ALLOPURINOL; ANTINEOPLASTIC AGENT; ASPARAGINASE; ASPARAGINASE MEDAC; ASPARAGINE; ASPARTIC ACID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC AGENT; DAUNORUBICIN; GLUTAMIC ACID; GLUTAMINE; MERCAPTOPURINE; METHOTREXATE; MIDAZOLAM; PETHIDINE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BEHAVIOR DISORDER; BLEEDING; BRAIN DISEASE; BRAIN PSEUDOTUMOR; CANCER COMBINATION CHEMOTHERAPY; CEREBROSPINAL FLUID ANALYSIS; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; COGNITIVE DEFECT; COMA; CONFUSION; CONTROLLED STUDY; CONVULSION; DRUG CEREBROSPINAL FLUID LEVEL; ELECTROENCEPHALOGRAM; ENCEPHALOMYELITIS; FEMALE; HUMAN; HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; LETHARGY; LEUKOCYTE COUNT; MALE; MENINGITIS; NEUROTOXICITY; POLYNEUROPATHY; PRIORITY JOURNAL; PSYCHOSIS; SLOW BRAIN WAVE; SOMNOLENCE; THROMBOEMBOLISM; TREATMENT OUTCOME;

ADOLESCENT; AMINO ACIDS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN DISEASES; CHILD; CHILD, PRESCHOOL; ELECTROENCEPHALOGRAPHY; FEMALE; HUMANS; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE;

EID: 0036887907     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/mpo.10189     Document Type: Article

References (42)

1. Vainionpää L. Clinical neurological findings of children with acute lymphoblastic leukaemia at diagnosis and during treatment. Eur J Pediatr 1993:115-119.
2. Lobo Antunes N. Acute neurologic complications in children with systemic cancer. J Child Neurol 2000;15:705-716.
3. Lichter-Konecki U, Benninger C, Brandeis WE, et al. Changes in the EEG background activity of children with acute lymphoblastic leukemia during cytotoxic therapy. Pediatr Hematol Oncol 1987;4:77-85.
4. Korinthenberg R, Igel B. Prospective neurophysiological study in children treated for acute lymphoblastic leukemia: Serial EEG during treatment and long-term follow up with evoked potentials. EurJ Pediatr 1990;150:127-130.
5. Vainionpää L, Saukkonen AL, Lanning M. Initial electroencephalographic findings in children with acute lymphoblastic leukaemia. Acta Paediatr Scand 1991;80:349-354.
6. Petersén I, Eeg-Olofsson O. The development of the electroencephalogram in normal children from the age 1 through 15 years. Non-paroxysmal activity. Neuropaediatrie 1971;2:247-304.
7. Boos J, Weber G, Ahlke E, et al. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. Eur J Cancer 1996;32A:1544-1550.
8. Mahoney DH, Britt CW, Kellaway P, et al. Childhood leukemia: Implications of EEG findings at time of diagnosis. J Pediatr 1981; 98:437-440.
9. Sainio K, Rautonen J, Siimes MA. Value of EEG in childhood acute lymphoblastic leukemia. Neuropediatrics 1989;20:82-83.
10. Jaffe N. Metabolic and biochemical changes in leukemia. Mod Probl Paediat 1975;16:113-136.
11. Bremer HJ, Duran M, Kamerling JP, et al., editors. Disturbances of amino acid metabolism: Clinical chemistry and diagnosis Baltimore, Munich: Urban & Schwarzenberg; 1981.
12. Gerrits GP, Trijbels FJ, Monnens LA, Gabreels FJ, De Abreu RA, Theeuwes AG, van Raay-Selten B. Reference values for amino acids in cerebrospinal fluid of children determined using ion-exchange chromatography with fluorimetric detection. Clinica Chimica Acta 1989;182:271-280.
13. Kotte W, Korth G, von Löbbecke J, Todt H. EEG-Befunde während der Vincristin-Therapie. Dt Gesundh Wesen 1976;31:2476-2479.
14. Korinthenberg R, Palm D, Rübig G, Schellong G. EEG changes during intensified induction therapy of acute lymphoblastic leukemia. Neuropediatrics 1979;10:332-347.
15. Epstein CM, Humphries LL, Alvarado CS, et al. Sequential quantitative EEG analysis in acute lymphocytic leukemia of children. Clin Electroencephalogr 1985;16:208-212.
16. Drigan R, Spirito A, Gelber RD. Behavioral effects of corticosteroids in children with acute lymphoblastic leukemia. Med Pediatr Oncol 1992;20:13-21.
17. Waber DP, Carpentieri SC, Klar N, et al. Cognitive sequelae in children treated for acute lymphoblastic leukemia with dexamethasone or prednisone. J Pediatr Hematol Oncol 2000;22:206-213.
18. Bleistein J, Braeunig P. EEG-Befunde bei Kortisonpsychosen - Eine retrospektive Untersuchung bei zehn Patienten. Z EEG-EMG 1989;20:112-116.
19. Hanefeld F, Riehm H. Therapy of acute lymphoblastic leukemia in childhood: Effects on the nervous system. Neuropediatrics 1980; 11:3-16.
20. Massimo L. Toxische Nebenwirkungen des Daunomycins bei Kindern. Blut 1970;20:44-56.
21. Ochs JJ. Neurotoxicity due to central nervous system therapy for childhood leukemia. Am J Pediatr Hematol Oncol 1989;11:93-105.
22. Kaplan RS, Wiernik PH. Neurotoxicity of antineoplastic drugs. Sem Oncol 1982;9:103-130.
23. Korinthenberg R, Ullrich K, Ritter J, Stephani U. Electrolytes, amino acids and proteins in lumbar CSF during the treatment of acute leukemia in childhood. Acta Paediatr Scand 1990;79:335-342.
24. O'Callaghan MJ, Ekert H. Vincristine toxicity unrelated to dose. Arch Dis Child 1976;51:289-292.
25. Whittaker JA, Parry DH, Bunch C, et al. Coma associated with vincristine therapy. Br Med J 1973;4:335-337.
26. Johnson FJ, Bernstein ID, Chard RL. Seizures associated with vincristine sulfate therapy. J Pediatr 1973;82:699-702.
27. Groebe H, Palm D. Vincristin-induzierte Encephalopathien unter der Behandlung kindlicher Leukosen. Monatsschr Kinderheilkd 1972;120:23-27.
28. Hurwitz RL, Mahoney DH, Armstrong DL, Browder TM. Reversible encephalopathy and seizures as a result of conventional vincristine administration. Med Pediatr Oncol 1988;16:216-219.
29. Amand G, Cornu G. Aspects électroencéphalographiques des complications centrales du traitement à la vincristine. Rev EEG Neurophysiol Clin 1974;4:479-483.
30. Lansky SB, List MA, Lansky LL, et al. The measurement of performance in childhood cancer patients. Cancer 1987;60:1651-1656.
31. Kingma A, Tamminga RY, Kamps WA, et al. Cerebrovascular complications of L-asparaginase therapy in children with leukemia: aphasia and other neuropsychological deficits. Pediatr Hematol Oncol 1993;10:303-309.
32. Müller HJ, Boos J. Use of L-asparaginase in childhood ALL. Crit Rev Oncol Hematol 1998;28:97-113.
33. Oettgen HF, Stephenson PA, Schwartz MK, et al. Toxicity of E. coli L-asparaginase in man. Cancer 1970;25:253-278.
34. Pratt CB, Roberts D, Shanks E, et al. Asparaginase in combination chemotherapy for remission induction of childhood acute lymphocytic leukemia. Cancer Research 1973;33:2020-2025.
35. Moure JMB, Whitecar JP, Bodey GP. Electroencephalogram changes secondary to asparaginase. Arch Neurol 1970;23:365-368.
36. Whitecar JP, Bodey GP, Harris JE, et al. L-asparaginase. N Engl J Med 1970;282:732-734.
37. Land VJ, Sutow WW, Fernbach DJ, et al. Toxicity of L-asparaginase in children with advanced leukemia. Cancer 1972;30:339-347.
38. Schwartz MK, Lash ED, Oettgen HF, et al. L-asparaginase activity in plasma and other biological fluids. Cancer 1970;25:244-252.
39. Miller HK, Salser JS, Balis ME. Amino acid levels following L-asparagine amidohydrolase therapy. Cancer Research 1969;29: 183-187.
40. Dibenedetto SP, Di Cataldo A, Meli C, et al. Levels of L-asparagine in CSF after intramuscular administration of asparaginase from Erwinia in children with acute lymphoblastic leukemia. J Clin Oncol 1995;13:339-344.
41. König R, Gutjahr P. EEG Befunde bei ALL Patienten 10 Jahre nach Bestrahlung und Zytostatikatherapie. Klin Pädiatr 1990;202:153-156.
42. Ueberall MA, Skirl G, Strassburg HM, et al. Neurophysiological findings in long-term survivors of acute lymphoblastic leukaemia in childhood treated with the BFM protocol 81 SR-A/B. Eur J Pediatr 1997;156:727-733.